Evaluate the Safety, Efficacy, and Pharmacokinetics of CRN04894 in Participants With Congenital Adrenal Hyperplasia (TouCAHn)
← catalyst calendarSponsored by Crinetics Pharmaceuticals Inc. (industry) · CRNX — their whole pipeline →.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Na · None · Treatment
Enrollment
38actual
Sites
27
Countries
Argentina, Brazil, Germany +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-07-03 | actual | When the study began enrolling |
| Primary completion | 2025-08-22 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-08-22 | actual | The whole study's end, after follow-up |
| First posted | 2023-06-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-09-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Congenital Adrenal Hyperplasia
- Classic Congenital Adrenal Hyperplasia
Intervention
- Drug: atumelnant (CRN04894)
Primary outcomes
what the primary-completion date above is the date OFChange from baseline in morning (before 11:00) serum androstenedione (A4)
measured Week 12
Incidence of treatment-emergent adverse events (TEAEs) throughout the study
measured Week 12
Permalink · CRNX's whole pipeline · Catalyst calendar · Every registered study · What changed